Cardiolipin

What is cardiolipin?

Cardiolipin (CL) is a unique dimeric phospholipid found almost exclusively on the inner mitochondrial membrane (IMM). It consists of two phosphatidic acid molecules linked by a glycerol backbone, giving it four fatty acid chains — unlike the two chains of conventional phospholipids. This distinctive structure creates a conical molecular shape that is essential for the curvature of mitochondrial cristae.

Cardiolipin comprises approximately 20% of the total lipid content of the inner mitochondrial membrane and is synthesized in situ — it is not imported from the endoplasmic reticulum like other mitochondrial phospholipids.

Functions

Electron transport chain organization

Cardiolipin is not merely a structural component — it is functionally required for the activity of every electron transport chain (ETC) complex. It stabilizes the supercomplexes (respirasomes) that organize Complexes I, III, and IV into efficient electron transfer units. Without cardiolipin, these supercomplexes disassemble, electron transfer becomes inefficient, and ROS production increases.

Cytochrome c anchoring

Cardiolipin electrostatically binds cytochrome c to the inner mitochondrial membrane, positioning it for efficient electron shuttling between Complex III and Complex IV. This interaction is functionally essential and is a primary target of the peptide SS-31.

Cristae structure

The curvature of cristae — the infoldings of the inner mitochondrial membrane that maximize surface area for oxidative phosphorylation — depends on cardiolipin's conical geometry. Cardiolipin depletion causes cristae to flatten, reducing the membrane surface available for ATP synthesis.

Mitochondrial dynamics

Cardiolipin participates in mitochondrial fission and fusion — the dynamic processes by which mitochondria divide and merge to maintain network health. It also serves as an "eat me" signal when externalized to the outer mitochondrial membrane, triggering mitophagy (selective autophagy of damaged mitochondria).

Apoptosis regulation

During programmed cell death, cardiolipin oxidation by cytochrome c releases cytochrome c from the membrane into the cytoplasm, where it activates the caspase cascade. Cardiolipin thus serves as a molecular switch between normal respiration and apoptosis.

Cardiolipin and aging

Cardiolipin undergoes characteristic changes with aging:

• Oxidation: Cardiolipin's four unsaturated fatty acid chains make it highly susceptible to oxidation by the ROS generated at the ETC complexes it supports — a vicious cycle. Oxidized cardiolipin loses its ability to anchor cytochrome c and maintain supercomplex structure.
• Depletion: Total cardiolipin content decreases with age in multiple tissues — heart, brain, liver, skeletal muscle.
• Remodeling defects: The enzyme tafazzin, which remodels cardiolipin's fatty acid composition, may decline in activity with age.

The consequence is progressive ETC dysfunction — less efficient ATP production, increased ROS generation, and impaired mitochondrial quality control. This cardiolipin-centered decline is increasingly recognized as an upstream driver of age-related mitochondrial dysfunction, rather than a downstream consequence.

Barth syndrome

Barth syndrome is a rare X-linked genetic disorder caused by mutations in the tafazzin gene, resulting in abnormal cardiolipin remodeling. It presents with cardiomyopathy, skeletal myopathy, neutropenia, and growth retardation — demonstrating the systemic consequences of cardiolipin dysfunction. SS-31 (elamipretide) has orphan drug designation for Barth syndrome based on clinical trial data showing improvements in 6-minute walk distance and cardiac function.

Peptide targeting: SS-31

SS-31 (elamipretide, Bendavia) is a cell-permeable tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH₂) that concentrates approximately 1000-fold in the inner mitochondrial membrane by binding to cardiolipin. Its mechanism:

• Stabilizes cardiolipin-cytochrome c interactions — restoring electron transfer efficiency
• Reduces ROS generation at the source — by improving ETC complex organization rather than scavenging ROS after they are produced
• Preserves cristae structure — maintaining the membrane architecture required for oxidative phosphorylation

SS-31 represents a targeted approach to mitochondrial aging — rather than supplementing antioxidants (which have repeatedly failed in clinical trials), it repairs the structural substrate from which excess ROS originates. This upstream targeting distinguishes it from conventional antioxidant strategies.